At the health systems level, lack of diagnostic ability, inadequate access to trained providers, and limited drug availability provide significant barriers to cancer care delivery. This article outlines an urgent call to action to improve access to precision oncology therapies in lower- and middle-income countries, drawing upon lessons from international efforts in oncology and infectious disease.

This article reports a case of malignant peritoneal mesothelioma (MPM) with STRN-ALK fusion in a 17-year-old female, the first known case with fusion of exon 2 of STRN and exon 20 of ALK.

This article evaluates the development of peripheral neuropathy related to paclitaxel treatment and the effect of dose reduction on post-treatment neuropathy outcomes.

This updated analysis based on data pooled from the three PALOMA studies is the largest long-term analysis, to date, of the safety of a CDK4/6 inhibitor in combination with endocrine therapy for the treatment of advanced breast cancer.

This study evaluated 528 patients with urothelial carcinoma and provides insight into the genetics and clinical features that distinguish PD-L1 positive and PD-L1 negative tumors.

Novel molecular targeted therapies for gastric cancer are urgently needed. This article explores the mutational landscape covering somatic, germline, and microorganisms among a cohort of Chinese patients with gastric cancer. Findings provide insight on patient stratification and potential molecular targets, and for developing new treatment strategies for patients in China and worldwide.

Effective therapeutic regimens are lacking for patients with cancers of unknown primary (CUP). This article reports the clinic-pathological challenges associated with diagnosis of unfavorable CUP in the CUPSICO trial and suggests refinements for diagnostic algorithms.

This article evaluates the clinical outcomes of patients with well-differentiated high-grade neuroendocrine tumors treated with different cytotoxic regimens at Mayo Clinic.

The aim of this large cohort study was to define the clinical significance of the AJCC/CAP tumor regression grading system for locally advanced rectal cancer, which could potentially be used to select the patients who would benefit from more intensive adjuvant chemotherapy as well as to protect patients from excessive treatment.

This article reports on the effect of proton pump inhibitors on the pharmacology, efficacy and safety outcomes of patients with metastatic renal cell carcinoma treated with cabozantinib.

Several immune checkpoint inhibitors have been approved for the treatment of metastatic urothelial cell carcinoma, but a prognostic biomarker is needed. This article reports on the effect of the Glasgow prognostic score on survival outcomes in patients with metastatic urothelial cell carcinoma receiving immune checkpoint inhibitor therapy.

This review reports the health-related quality of life for patients with breast cancer living in Latin American countries and explores relationships with disease stage and treatment in real-world settings.

With a multinational collection of registry data and multimodal evaluation of degree of therapy guideline adherence, this study adds population-based evidence on the status of cervical cancer care and outcomes in the setting of sub-Saharan Africa.

This article describes the real-world demographic and clinical characteristics, as well as current treatment patterns, among patients diagnosed with diffuse large B-cell lymphoma (DLBCL) and treated in the United States. Health care resource use and associated costs are assessed.

This review describes the current pathologic understanding of chronic myelomonocytic leukemia (CMML), appraises risk factors and stratification models, details treatment options, and proposes a contemporary treatment algorithm for patients with CMML.

Systemic therapies for advanced hepatocellular carcinoma (HCC) can cause hypothyroidism. This study examined the prevalence and prognostic impact of hypothyroidism in patients with HCC before receiving any systemic therapy.

The absence of immune checkpoint inhibitor (ICI) safety data in cancer patients with hepatitis C virus infection (HCV) makes it challenging to assess the risk-benefit ratio of the therapy and to advise patients on the likelihood of adverse events to help them make informed decisions. This article reports a retrospective study of cancer patients with HCV untreated and resolved who received ICI therapy.

The role of family communication is recognized as an important factor in decision making for cancer patients near the end of life. This article discusses the value and role of family in end-of-life discussions and the challenges encountered by oncologist and oncology nurses when involving family in decision making.

Direct oral anticoagulants (DOACs) are a less burdensome treatment for cancer-associated thrombosis and have comparable safety and efficacy to low molecular weight heparin; however, there are little data to support the use of DOACs in patients with brain tumors. This article reports on the safety profile of anticoagulants in patients with primary and metastatic brain tumors, focusing on the safety and efficacy of DOACs.

Different subgroups of anaplastic gliomas have been established. This study compared two chemotherapies in combination with radiotherapy to determine best management of IDH-mutant anaplastic astrocytomas.

The use of a therapeutic cancer vaccine that stimulates the immune system to fight brachyury-expressing cancer cells is a promising alternative to targeted molecular therapies. This article evaluates the concurrent use of a yeast-brachyury vaccine in combination with radiation therapy in patients with advanced or metastatic chordoma.

Drug development in oncology has broadened from mainly considering randomized clinical trials to also including single-arm trials tailored for very specific subtypes of cancer. They often use historical controls, and this article discusses benefits and risks of this paradigm and provide regulatory and statistical considerations.

This review summarizes the FDA perspective and data supporting the approval of atezolizumab and durvalumab for use in combination with chemotherapy for first-line treatment of patients with extensive stage small cell lung cancer.

Pexidartinib is approved in the U.S. for treatment of tenosynovial giant cell tumors (TGCT). This article assesses the hepatic safety profile of pexidartinib in TGCT cases and describes risk mitigation procedures designed to identify any instances of serious liver injury as early as possible to better inform prescribers and patients about this drug.

Obesity is associated with an increased risk of cancer. This study sought to examine the differences in clinical-pathological and psychosocial variables between individuals with and without obesity who had stage II to III colon cancer and received adjuvant chemotherapy.

This randomized trial assessed the effect of high-flow oxygen, high-flow air, low-flow oxygen, and low-flow air on dyspnea in hospitalized cancer patients without hypoxemia.

Cancer treatment-related effects remain a challenge in neuro-oncology. This brief communication presents a case series of patients diagnosed with intracranial foreign body granuloma.

Immunomodulation by immune checkpoint inhibitors (ICIs), which are used to treat advanced cancers, has an uncertain effect on COVID-19 susceptibility. This brief communication compares infection risk between cancer patients with and without a history of ICI treatment.

This letter to the editor remarks on a recently published article on the use of NUC-1031 and cisplatin for patients with biliary tract cancer and compares results of the landmark ABC-02 trial.

This letter to the editor outlines the use of stereotactic body radiotherapy for metastatic renal cell carcinoma in the U.S., identifying clinical predictors of utilization using the National Cancer Database.

Prioritizing self-care over the ever-present to-do list is important, especially during the COVID-19 pandemic, as this narrative describes.

In memory of José Baselga